DrugInformations.org

If you are planning to go to the Glastonbury music festival this weekend and your prayers for a dry and warm few days aren’t answered, you might like to heed BBC reporter Andy Sully’s advice and look after your feet, or you could end up with trench foot, as he did last year. The Glastonbury Festival of Contemporary Performing Arts, better known as Glastonbury or Glasto, is the largest music and performing arts festival of its kind in the world.

More: continued here

No Comments »

Ipsen (Paris:IPN) announced that the European Commission granted marketing authorisation for Adenuric® (febuxostat) for the treatment of chronic hyperuricaemia in gout. Adenuric® thus pioneers the first major treatment alternative for gout, a severe debilitating disease, for more than 40 years.

More: continued here

No Comments »

A study led by a team of scientists in Scotland suggests that genes may play a part in increasing one’s risk of developing gout, a painful condition that affects the joints.The study is published in the 9 March online issue of Nature Genetics and is the work of researchers based at the MRC Human Genetics Unit, Western General Hospital, Edinburgh, and colleagues from other research centres in the UK and also in Croatia and Germany.

More: continued here

No Comments »

Ipsen (Paris:IPN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) provided a positive opinion for Adenuric® (febuxostat) 80 mg and 120 mg tablets for the treatment of chronic hyperuricaemia in gout and recommended it for marketing authorisation. The CHMP recommendation will now be forwarded to the European Commission for final marketing approval, which typically occurs within 60 to 90 days.

More: continued here

No Comments »

“Soft drinks ‘bigger gout risk than alcohol’” read the headline in The Daily Telegraph today. It reported that “drinking too many sugary soft drinks and fruit juices can substantially increase the risk of gout”. Gout can be extremely painful and is caused by a build up of uric acid that crystallises in the joints. Uric acid is formed by the breakdown of purines which occur naturally in the body as well as in the diet.

More: continued here

No Comments »

According to a recent study published on bmj.com,men who drink sugary soft drinks and eat fructose have an increasedrisk of gout.Gout is a disease caused by a buildup of uric acid in the blood(hyperuricemia) that provokes an inflammatory reaction in tissues andjoints. It is often painful and is most common in men 40 years of ageand older. Over the last few decades, levels of gout in the UnitedStates have doubled.

More: continued here

No Comments »

Coffee is a habit for more than 50 percent of Americans, who drink, on average, 2 cups per day. This widely consumed beverage is regularly investigated and debated for its impact on health conditions from breast cancer to heart disease. Among its complex effects on the body, coffee or its components have been linked to lower insulin and uric acid levels on a short-term basis or cross-sectionally. [click link for full article]

More: continued here

No Comments »

High uric acid levels in the blood are a precursor of gout, the most common inflammatory arthritis in adult men. It is believed that coffee and tea consumption may affect uric acid levels but only one study has been conducted to date. A new large-scale study published in the June 2007 issue of Arthritis Care & Research (http://www.interscience.wiley. [click link for full article]

More: continued here

No Comments »

People with gout are at increased risk of having a heart attack, according to a University of Pittsburgh School of Medicine study published in the August edition of the journal Arthritis & Rheumatism. The article is available on line at http://www3.interscience.wiley.com/cgi-bin/jhome/76509746. [click link for full article]

More: continued here

No Comments »

OSAKA, JAPAN — Takeda Pharmaceutical Company Limited (”Takeda”) announced today that TAP Pharmaceutical Products Inc (”TAP”), its 50-50 joint venture with Abbott Laboratories, submitted a New Drug Application (”NDA”) on December 14 with the US Food and Drug Administration for febuxostat 80mg and 120mg for the management of hyperuricemia in patients with chronic gout. [click link for full article]

More: continued here

No Comments »